April 19, 2024
Bio
Daewoong Pharma tops list of clinical study approvals
[THE INVESTOR] Daewoong Pharmaceutical has bagged the most approvals from the drug regulatory agency for clinical trials, industry officials said on Feb. 7.
Daewoong received approvals from the Ministry of Food and Drug Safety for 16 clinical trials in 2016, compared with seven a year earlier. According to the company, they include 11 phase 1 studies and two phase 2 studies for eventual development of such drugs as anti-ulcer drugs.
The company said it has won approvals for two studies on expanding the scope of treatment using botulinum toxin type A, which is marketed as Nabota. Nabota, which is administered via injections, can improve frown lines and temporary arm paralysis, according to Daewoong.
The company is also trying to treat post-stroke upper limb spasticity with Nabota.
(theinvestor@heraldcorp.com)
Daewoong received approvals from the Ministry of Food and Drug Safety for 16 clinical trials in 2016, compared with seven a year earlier. According to the company, they include 11 phase 1 studies and two phase 2 studies for eventual development of such drugs as anti-ulcer drugs.
The company said it has won approvals for two studies on expanding the scope of treatment using botulinum toxin type A, which is marketed as Nabota. Nabota, which is administered via injections, can improve frown lines and temporary arm paralysis, according to Daewoong.
The company is also trying to treat post-stroke upper limb spasticity with Nabota.
(theinvestor@heraldcorp.com)
